Selling Your Imaging Center: What Buyers Actually Pay

In September 2023, the Federal Trade Commission sued the private-equity firm Welsh, Carson, Anderson & Stowe over an anesthesia roll-up — and the case cited the firm's own stated intent to deploy a similar strategy in radiology through its imaging platform, US Radiology Specialists (FTC). That is not a forecast. RadNet has allocated more than $340 million to acquisitions in 2026 alone — AI capabilities and imaging centers both (Radiology Business, 2026); SimonMed (American Securities), RAYUS (Wellspring), and Akumin (Stonepeak) are all PE-backed platforms consolidating centers like yours.

So a buyer will call. The number they open with is not the number you will get.

Key Takeaway: Buyers do not pay on the EBITDA your P&L shows — they pay on Adjusted EBITDA that survives a Quality of Earnings (QofE) review. There are really three numbers, not one: the headline multiple in the Letter of Intent (which wins your exclusivity), the cleared price after diligence resets it, and the cash at close after rollover, earnout, and escrow — which can sit well below the headline. Real 2026 imaging multiples are documented (RadNet has said on the record it buys small tuck-ins at roughly 4–7x EBITDA, while scaled public platforms trade closer to 10–12x — the gap that powers the roll-up), and the structure is where most owners lose ground. Imaging is also really two businesses — durable radiology and volatile PET-tracer income — and buyers price that mix as a discount. Before any of it, answer the one question that sets your price: are you selling a fixer-upper or a walk-in-ready center? You can get a defensible estimate of your Adjusted EBITDA now, or learn it in the data room. A Strategic Radiology Review gets you the first.

The Three Numbers: Headline, Cleared, Cash at Close

Owners think a sale is one number times one multiple. It is three numbers, and they fall in sequence:

1. The headline — the price in the Letter of Intent (LOI). It is non-binding, it is usually the top of the range, and its real job is to win your exclusivity.
2. The cleared price — what survives diligence, after the buyer reconstructs your earnings and applies a multiple to that.
3. The cash at close — what actually hits your account after rollover equity, earnout, and escrow are carved out of the cleared price.

The gap between number 1 and number 3 is where deals disappoint. Everything below is about closing that gap before a buyer opens it for you.

What Buyers Actually Pay On: SDE vs EBITDA vs Adjusted EBITDA

Which earnings figure a buyer uses depends on your size, and confusing the three is the most common reason owners walk in with the wrong expectation.

The convention among M&A advisors is that businesses under roughly $1 million in earnings are valued on SDE, and above that line on EBITDA (Morgan & Westfield). The trap: SDE adds your salary back (a small buyer steps into your seat), so SDE multiples are lower — small businesses generally trade around 2–4x SDE. Adjusted EBITDA subtracts a market-rate manager (a platform hires one). Apply a platform EBITDA multiple to an SDE number and you have double-counted your own paycheck.

What the documented imaging multiples actually are in 2026:

That spread is the roll-up: a buyer acquires your single center in the ~4–7x tuck-in range and folds it into a platform the public market values at ~10–12x or more. The arbitrage is the entire reason you are being approached — and it is why the buyer's discipline on your number is absolute. (For the buy-side view of the same math, see How to Acquire a Second Imaging Center.)

The Friendly LOI, Then the Reset

The sale process has a predictable shape, and the leverage shifts at a specific moment.

1. The LOI. A buyer offers an attractive headline number. It is non-binding by design; its job is less to set the final price than to win your exclusivity and frame the deal.
2. The no-shop. You sign, agreeing not to talk to other buyers — typically for 30–90 days, with PE buyers pushing the longer end. The moment you do, the competing bids leave the room and your leverage transfers to the buyer (Newport LLC).
3. Diligence and Quality of Earnings. The buyer reconstructs your earnings line by line. Normalized-EBITDA / QofE work is where reported profit meets defensible profit, and where price gets reset (Morgan & Westfield, QofE guide).
4. The reset. Findings become price adjustments, or value gets pushed into contingent structure.

A word on honesty: there is no credible survey putting a "percentage of deals that get retraded" on corporate M&A — the widely-quoted 40–60% figure is from commercial real estate, not company sales, and you should distrust anyone who quotes it here. What the data does show is the structural cousin of the reset: buyers increasingly push value into earnouts. About one-third of private-target deals now carry an earnout, and the median earnout has grown to roughly 43% of the closing payment (SRS Acquiom 2024 Deal Terms Study). The headline holds; the certainty moves.

The reset is rarely fraud-hunting. It is built from your own EBITDA bridge — the "one-time" expense that recurs every year, the family member on payroll a buyer must replace, deferred maintenance, a concentrated referral source. The general-business version of this — an LOI that fell sharply once the inspection report came back — is in Fixer Upper or Walk-In Ready. The defense is not better negotiating. It is removing the ammunition before the no-shop is signed.

The Number Behind the Number: Deal Terms That Decide Your Cash at Close

The multiple is the easiest thing for a buyer to concede, because the structure is where the economics live. These ranges are from the SRS Acquiom 2024 study and mainstream M&A practice:

The most misread term is rollover equity. Done well, it is a genuine "second bite of the apple" — the rolled stake can return as much as the cash at close when the platform sells again (Colonnade). Done badly, it is a minority position you cannot sell until the sponsor exits, often junior to the sponsor's preferred return. Rollover is not lost money — it is contingent, illiquid money. A headline that looks like 5–6x can leave the cash you can actually spend at close materially lower, with the rest riding on someone else's platform and timeline. That is the gap between number 1 and number 3.

A simplified illustration (round numbers, not a real deal, to show the mechanics):

• A center reports $2.0M EBITDA. An LOI lands at 5x — a $10.0M headline.
• Diligence normalizes EBITDA to $1.7M: a recurring "one-time" expense disallowed, owner comp reset to market, a concentrated referral source haircut.
• The buyer applies a multiple at the lower end of the range — say 4.5x — because a meaningful share of profit rides on volatile PET-tracer income. Cleared price ≈ $7.7M.
• After 20% rollover and an earnout, the cash at close might be **$5M**.

The $10M headline was never the deal. Every step there is something you can model — and improve — before a buyer ever runs it.

Imaging Is Two Businesses — and Buyers Price the Mix

Here is the part general-practice advisors miss, and the part to state carefully so it survives scrutiny. A modern imaging center is really two businesses: a durable Radiology Unit (MRI, CT, ultrasound, X-ray, standard PET) and a volatile PET Tracer Unit (high-reimbursement specialty tracers).

A buyer does not write your PET line a separate check at a separate multiple — sum-of-the-parts is a useful way to see the risk, not how a deal clears. What actually happens is one or more of three things: the buyer applies a lower blended multiple to the whole business, haircuts the volatile EBITDA before applying the multiple, or pushes more of the price into an earnout tied to that income holding up. Different mechanism, same result — concentrated, payer-volatile PET income is worth less to a buyer than durable radiology income.

Why PET income carries that discount, with the real regulatory context:

• Reimbursement uncertainty. CMS retired the national coverage determination for amyloid PET (NCD 220.6.20) effective October 13, 2023, ending the once-per-lifetime limit and handing coverage decisions to regional contractors — so coverage and payment now vary by region and payer (CMS; ACR).
• Shifting payment mechanics. Starting January 1, 2025, Medicare began paying separately for high-cost diagnostic radiopharmaceuticals (those above ~$630 per day) in the hospital outpatient setting — a change that re-prices the economics of the tracer itself (CMS CY2025 OPPS fact sheet).
• Up-front cost and denial risk. A complete amyloid PET scan can run several thousand dollars out of pocket, and the tracer cost is incurred before the claim is collected — and lost on a denial or no-show. The income is high-dollar but concentrated and lumpy.

The implication for a seller is counterintuitive: a center more dependent on PET for its profit can carry a lower blended multiple, not a higher one — because that income is the part a buyer trusts least. Show a buyer a durable radiology base with PET as upside and you defend the multiple. Hand them a blended P&L and they assume the worst about the mix. The seller who has read their own per-modality profitability negotiates from a stronger position than the one who learns it from the buyer's report.

Will the Buyer Keep Your Team — or Replace It?

Sellers present their best month. Buyers underwrite the trend and the org chart — and together they decide whether your management is an asset they keep or a cost they cut.

• If the trend is up and operations are institutionalized, the buyer keeps the team, pays a fuller multiple, and may want only light involvement from you.
• If you are the rainmaker — referrals flow through your relationships — the buyer sees key-man risk and responds with an employment agreement, a retention-weighted earnout, and a discount for the transition.
• If the trend is down, the buyer assumes they must strengthen or replace management and absorb the disruption, and prices that in before you ever see the number.

A buyer is not buying last year. They are buying the slope of the last couple of years and whether the business survives your departure.

Are You Selling a Fixer-Upper or a Walk-In-Ready Center?

This is the one question that sets your price, and you can answer it before a buyer does. A fixer-upper business gets a fixer-upper price — every time.

A walk-in-ready center has clean reconciled books, a diversified referral base, a balanced payer mix, modern equipment with no capex cliff, positive equity, improving trends, and a PET-vs-radiology split that is legible rather than buried. A fixer-upper has the opposite, and it still sells — at a fixer-upper price, with more pushed into earnout and escrow. Grade your own center the way a buyer will, using the defect list in Fixer Upper or Walk-In Ready, then decide: take the fixer-upper price now, or spend 12–24 months renovating and go to market walk-in-ready.

Quality of Earnings: Run Yours Before the Buyer Runs Theirs

A buyer-side QofE is a forensic reconstruction of defensible, forward-looking earnings, and on a sale of any size the buyer will run one. The only question is whether you ran yours first. The principle that value tracks defensible earning capacity and risk is old — the IRS leaned on it in Revenue Ruling 59-60 back in 1959 for a different purpose, valuing closely held stock for estate tax. A QofE applies the same instinct to a sale.

Sell-side readiness, in practice:

1. Build the buyer's EBITDA bridge yourself — every add-back labeled "will survive" or "will get cut," with documentation attached to each survivor.
2. Separate the two business units — clean PET vs Radiology economics, so the mix tells your story instead of the buyer's.
3. Stress the revenue durability — referrer concentration, payer mix, PET coverage exposure. Find the haircuts first.
4. Reconcile your sources — operational billing data, the accounting system, and bank-grade aged receivables, to a tight and explainable variance, so receivables credibility removes one reset lever.
5. Normalize owner compensation to market — so your Adjusted EBITDA is a number a platform buyer will underwrite.

If you are financing the buyer's side instead, the SBA's acquisition-financing programs underwrite to that same defensible-earnings number — one more reason the seller who has it ready closes cleaner.

To be clear about scope: this is financial-readiness work — a defensible estimate of your Adjusted EBITDA and the diligence findings most likely to move price. It is not a certified business valuation or M&A advisory; for a formal valuation opinion or to run the transaction, we coordinate with credentialed valuation and investment-banking specialists. The operator's-eye view behind it is described on our about page.

The number a buyer pays is not the number on your P&L. It is the number that survives the data room — the cleared price, and the cash at close beneath it — and every one of those numbers can be estimated and strengthened years before you sign an LOI. The owner who knows all three walks into the room defending a number instead of hoping for one. That is the difference a year of preparation makes, and it is the quietest edge in the entire transaction.

Frequently Asked Questions

How much is my imaging center worth in 2026? A single center or small tuck-in commonly trades around 4–7x EBITDA — the range RadNet's CFO has said on the record the company pays — while scaled public imaging platforms trade closer to 10–12x trailing EBITDA (VMG Health). Owner-operated centers under about $1M earnings are often priced on a 2–4x SDE multiple instead. The exact number inside the range is decided in diligence, not in the LOI.

Why does a private-equity buyer lower the price after the LOI? The LOI is a non-binding offer whose main job is to win your exclusivity. Once you sign the no-shop, the diligence and Quality of Earnings team can reset the price using your own add-backs, deferred capex, and revenue-concentration gaps. It is a structural feature of the process, not necessarily bad faith — which is why running your own QofE first removes most of the leverage. (There is no credible survey on how often this happens in company M&A; the 40–60% "retrade" figure often quoted is from commercial real estate, not business sales.)

What deal terms matter besides the multiple when selling an imaging center? Cash at close, rollover equity (10–30%), earnout (about a third of deals, median ~43% of the closing payment), escrow/holdback (1% of value, or a small RWI retention), the working-capital peg, reps and warranties, and the employment agreement plus non-compete. A 5–6x headline can leave materially less than that as certain cash at close, with the rest contingent or illiquid.

Does my PET tracer business make my imaging center worth more or less? It can lower your blended multiple. PET tracer income is high-dollar per claim but concentrated, payer-variable (amyloid PET lost its national Medicare coverage determination in October 2023, so coverage now varies by region), and carries a tracer cost incurred before the claim is collected. Buyers price that risk through a lower blended multiple, an EBITDA haircut, or a larger earnout — so a center over-dependent on PET often clears lower, not higher.

How early should I prepare to sell my imaging center? Two to five years out. The drivers that move your multiple — referral diversification, payer mix, the PET/radiology split, ending recurring "one-time" costs, three to four quarters of improving trend — take quarters to fix, not weeks. A seller who runs their own Quality of Earnings early clears closer to the headline than one who first sees the analysis in the buyer's report.

Thinking about selling — or already holding an LOI? A Strategic Radiology Review reconstructs a defensible estimate of your Adjusted EBITDA, separates your PET and Radiology economics, grades your center fixer-upper vs walk-in-ready, and surfaces the diligence findings most likely to move price — before you sign a no-shop. Fixed fee, two-week turnaround. Start the conversation →

Disclaimer: This article is for informational purposes only and does not constitute tax, legal, financial, valuation, or investment-banking advice. Multiples, deal terms, and reimbursement policy change and vary by transaction, region, and payer — verify current specifics for your situation. Benefique provides financial-readiness analysis, not certified business valuations or M&A advisory services. Any illustrative figures are simplified examples, not real client transactions.